Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm
- 19 February 2021
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 127 (5) , 498-506
Abstract
Objectives: To examine the current molecular therapeutics in the medical treatment of recurrent ischemic priapism (RIP). To propose a stepwise clinical management paradigm for the treatment of RIP. Methods: We performed a literature search using the PubMed database for the terms ‘recurrent ischemic priapism’ and ‘stuttering priapism’ up until December 2020. We assessed pre‐clinical and clinical studies regarding medical management of RIP and molecular pathophysiology. Case series and randomized trials were evaluated by study quality and patient outcomes to determine a potential clinical management scheme. Results: Recent research has fostered an improved understanding of the underlying molecular pathophysiology of RIP that has paved the way forward for developing new therapeutic agents. Medications targeting neurovascular, hormonal and haematological mechanisms associated with RIP show great promise towards remedying this condition. A host of therapeutic agents operating across different mechanistic directions may be implemented according to a clinical management scheme to potentially optimize RIP outcomes. Conclusion: RIP remains a medically neglected condition with current management focused on treating the acute condition rather than modulating the course of disease. Continued research into the molecular mechanisms of RIP and standardized clinical pathways can improve the quality of care for patients suffering from this condition.Keywords
This publication has 61 references indexed in Scilit:
- Sildenafil Citrate-Restored eNOS and PDE5 Regulation in Sickle Cell Mouse Penis Prevents Priapism Via Control of Oxidative/Nitrosative StressPLOS ONE, 2013
- Corporal Burnett “Snake” Surgical Maneuver for the Treatment of Ischemic Priapism: Long-Term FollowupJournal of Urology, 2013
- Standard Operating Procedures for PriapismThe Journal of Sexual Medicine, 2013
- A Prospective Diary Study of Stuttering Priapism in Adolescents and Young Men With Sickle Cell Anemia: Report of an International Randomized Control Trial--The Priapism in Sickle Cell StudyJournal of Andrology, 2010
- Endothelial regulation of eNOS, PAI-1 and t-PA by testosterone and dihydrotestosterone in vitro and in vivoMolecular Human Reproduction, 2010
- Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent PriapismThe Journal of Sexual Medicine, 2006
- Phosphodiesterase 5 Mechanisms and Therapeutic ApplicationsThe American Journal of Cardiology, 2005
- LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIALJournal of Urology, 2005
- Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrineUrology, 1996
- Neurologic events after partial exchange transfusion for priapism in sickle cell diseaseThe Journal of Pediatrics, 1992